ResearcherCenter of Medical Innovation and Translational Research, The University of OsakaNo recent work listed
Katsunori Matsushita
Matched on ORCID iD 0009-0000-1151-0258; OpenAlex author ID A5007182236. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 17
2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper
Papers 4
- Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cnr2.1582↗
- A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cmdc.201900324↗
- Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. Co-author DOI 10.3892/ol.2018.8357↗
- [Nab-Paclitaxel plus Gemcitabine for Metastatic Pancreatic Cancer]. Co-author PMID 26805366↗
Closest collaborators
The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Tadafumi Asaoka · 3 shared papers, 2018–2022 · strength 0.27
- Paper Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. DOI 10.1002/cnr2.1582↗
- Paper A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cmdc.201900324↗
- Paper Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. DOI 10.3892/ol.2018.8357↗
- Ayumu Asai · 3 shared papers, 2018–2022 · strength 0.27
- Paper Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. DOI 10.1002/cnr2.1582↗
- Paper A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cmdc.201900324↗
- Paper Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. DOI 10.3892/ol.2018.8357↗
- Yuichiro Doki · 3 shared papers, 2018–2022 · strength 0.27
- Paper Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. DOI 10.1002/cnr2.1582↗
- Paper A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cmdc.201900324↗
- Paper Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. DOI 10.3892/ol.2018.8357↗
- Yoshifumi Iwagami · 3 shared papers, 2018–2022 · strength 0.27
- Paper Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. DOI 10.1002/cnr2.1582↗
- Paper A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cmdc.201900324↗
- Paper Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. DOI 10.3892/ol.2018.8357↗
- Hidetoshi Eguchi · 3 shared papers, 2018–2022 · strength 0.27
- Paper Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. DOI 10.1002/cnr2.1582↗
- Paper A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cmdc.201900324↗
- Paper Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. DOI 10.3892/ol.2018.8357↗
- Kunihito Gotoh · 3 shared papers, 2018–2022 · strength 0.27
- Paper Clinicopathological significance of MYL9 expression in pancreatic ductal adenocarcinoma. DOI 10.1002/cnr2.1582↗
- Paper A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cmdc.201900324↗
- Paper Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. DOI 10.3892/ol.2018.8357↗
- Hirofumi Akita · 2 shared papers, 2019–2022 · strength 0.21
- Hideshi Ishii · 2 shared papers, 2018–2022 · strength 0.20
- Daisaku Yamada · 2 shared papers, 2018–2019 · strength 0.13
- Paper A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/cmdc.201900324↗
- Paper Association of iron metabolic enzyme hepcidin expression levels with the prognosis of patients with pancreatic cancer. DOI 10.3892/ol.2018.8357↗
- Satoshi Obika · 1 shared paper, 2019 · strength 0.07
- Hideshi Ishii · 1 shared paper, 2019 · strength 0.07
- Reishi Toshiyama · 1 shared paper, 2018 · strength 0.06
- Tomofumi Ohashi · 1 shared paper, 2018 · strength 0.06
- Yoshiaki Ohmura · 1 shared paper, 2015 · strength 0.04
- Shigeyuki Tamura · 1 shared paper, 2015 · strength 0.04
- Yutaka Takeda · 1 shared paper, 2015 · strength 0.04
- Yoshiteru Katsura · 1 shared paper, 2015 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.